Biology of HER2 and its importance in breast cancer

Oncology

Volumn 61, Issue SUPPL. 2, 2001, Pages 1-13

  Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Breast cancer; HER2 (erbB 2, neu); Herceptin ; Monoclonal antibody; Network; Receptor; Signaling; Trastuzumab; Tumor growth

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; RECEPTOR SUBTYPE; TRASTUZUMAB;

BINDING AFFINITY; BREAST CARCINOMA; CANCER CELL; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL SURFACE; CONFERENCE PAPER; DIMERIZATION; DRUG EFFICACY; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC TRANSFORMATION; HUMAN; LIGAND BINDING; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; STROMA;

EID: 0034766736     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055396     Document Type: Conference Paper

References (80)

1. Tumor promoter and epidermal growth factor stimulate phosphorylation of the c-erbB-2 gene product in MKN-7 human adenocarcinoma cells
2. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
3. Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas
4. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
5. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
6. 1997 Update of recommendations for the use of tumour markers in breast and colorectal cancer
7. Development and characterization of a rhuMAb HER2 antibody assay for clinical evaluation of cytotoxic potency
8. The neu oncogene encodes an epidermal growth factor receptor-related protein
9. Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials
10. Receptor blockade with monoclonal antibodies as anticancer therapy
11. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired
12. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
13. Reduction of erbB2 gene product in mammary carcinoma cell lines by erbB2 mRNA specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides
14. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis
15. Neuregulin-2, a new ligand of erbB3/erbB4-receptor tyrosine kinases
16. Humanization of the anti-p185HER2 antibody for human cancer therapy
17. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification
18. What is HER2?
19. The epidermal growth factor receptor and the product of the neu-proto-oncogene are members of a receptor tyrosine phosphorylation cascade
20. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
21. Neu overexpression correlates with extent of disease in large cell ductal in situ carcinoma of the breast
22. Recent cancer trends in the United States
23. EGF-related peptides and their receptors in mammary gland development
24. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
25. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo
26. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo
27. Characterization of murine monoclonal antibodies reactive to either the human growth factor receptor or HER2/neu gene product
28. Insect cell-expressed p180ErbB3 possesses an impaired tyrosine kinase activity
29. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diaminedi-chloroplatinum against human breast and ovarian tumor cell lines
30. Oral cancer progression and c-erbB-2/neu proto-oncogene expression
31. Basic science of HER2/neu: A review
32. Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles
33. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake
34. The biology of erbB-2/neu/HER-2 and its role in cancer
35. Heregulin induced in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli
36. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
37. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies
38. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
39. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
40. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
41. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers
42. Coupling of the c-Cbl proto-oncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins
43. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
44. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor
45. Interaction between ERB-receptors and heregulin in breast cancer tumor progression and drug resistance
46. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer
47. Multiple essential functions of neuregulin in development
48. EGF-related peptides in the pathophysiology of the mammary gland
49. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
50. The predictive value of HER2 in breast cancer
51. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation
52. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network
53. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
54. Pattern of expression of c-erbB-2 oncoprotein in human fetuses
55. The Her-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
56. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer
57. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
58. Studies of the HER2/neu proto-oncogene in human and breast ovarian cancer
59. Co-expression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
60. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
61. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth
62. c-Cbl: A regulator of T cell receptor-mediated signaling
63. Bivalence of EGF-like ligands drives the ErbB signaling network
64. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
65. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
66. Amplification of the neu/c-erbB-2 oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene
67. Receptor protein-tyrosine kinases and their signal transduction pathways
68. Isolation and characterization of chicken DNA homologous to the two putative oncogenes of avian erythroblastosis virus
69. Over-expression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification
70. The carboxyl terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing
71. Alternative intracellular routing of ErbB receptors may determine signaling potency
72. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung
73. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma
74. Similarity of protein encoded by the human c-erb-2 gene to epidermal growth factor receptor
75. Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland
76. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue
77. Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas
78. Amplification and re-arrangement of c-erbB proto-oncogenes in cancer of human female genital tract
79. Identification of a geldanamycin dimer that induces selective degradation of HER-family tyrosine kinases